Biomarker modeling of alzheimer's disease

Clifford R. Jack, David M. Holtzman

Research output: Contribution to journalReview article

435 Scopus citations

Abstract

Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable invivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.

Original languageEnglish
Pages (from-to)1347-1358
Number of pages12
JournalNeuron
Volume80
Issue number6
DOIs
StatePublished - Dec 18 2013

Fingerprint Dive into the research topics of 'Biomarker modeling of alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this